Biogen Idec reports income of $1.

Biogen Idec reports income of $1.2 billion for second quarter 2011 Biogen Idec Inc kamagra postförskott click here . , a worldwide biotechnology innovator in the discovery, advancement, commercialization and production of innovative therapies, announced its second quarter 2011 results today. Second One fourth 2011 Highlights: Second one fourth revenues had been $1.2 billion, flat when compared to second quarter of 2010. Our talk about of RITUXAN revenues from our unconsolidated joint business was decreased by around $50 million through the second one fourth of 2011 because of an accrual associated with an intermediate decision in Genentech, Inc.’s ongoing arbitration with Hoechst GmbH.